1. Home
  2. PRTS vs SCYX Comparison

PRTS vs SCYX Comparison

Compare PRTS & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CarParts.com Inc.

PRTS

CarParts.com Inc.

HOLD

Current Price

$6.17

Market Cap

50.9M

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$4.73

Market Cap

44.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRTS
SCYX
Founded
1995
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Auto & Home Supply Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.9M
44.0M
IPO Year
2006
2014

Fundamental Metrics

Financial Performance
Metric
PRTS
SCYX
Price
$6.17
$4.73
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
$0.50
$3.00
AVG Volume (30 Days)
32.2K
78.7K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.36
EPS
N/A
N/A
Revenue
N/A
$257,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$5.25
$608.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.37
$0.57
52 Week High
$7.27
$5.62

Technical Indicators

Market Signals
Indicator
PRTS
SCYX
Relative Strength Index (RSI) 64.05 71.79
Support Level $5.91 $0.67
Resistance Level $6.46 $5.62
Average True Range (ATR) 0.33 0.30
MACD -0.20 -0.05
Stochastic Oscillator 19.92 90.83

Price Performance

Historical Comparison
PRTS
SCYX

About PRTS CarParts.com Inc.

CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. It serves as an end-to-end solution for automotive repair and maintenance resources, offering a seamless online shopping experience that empowers drivers along every part of their journey. The company principally sells its products to individual consumers through its network of websites and online marketplaces. Its products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: